

**Washington State Pharmacy and Therapeutics Committee & Drug Utilization Review Board**  
**Meeting by Zoom Webinar**  
**Wednesday, December 11, 2024, 11 a.m. to 5 p.m.**

| Agenda  |  |                                |
|---------|--|--------------------------------|
| Time    | Topic  | Presenter                      |
| 11 a.m. | <b>Welcome &amp; Introductions</b><br><b>Pharmacy &amp; Therapeutics (P&amp;T) Committee Convenes (Reviews drug classes for the WA PDL)</b><br><b>Committee vote on new Chair and Vice Chair</b>               | Kavita Chawla, Committee Chair |
|         | <b>Non-Asthma Biologics</b> <ul style="list-style-type: none"> <li>• Stakeholder Input*</li> <li>• Motion</li> </ul>   | Wesley Lindsey, DERP           |
|         | <b>ADHD</b> <ul style="list-style-type: none"> <li>• Stakeholder Input*</li> <li>• Motion</li> </ul>   | Shannon Robalino, DERP         |
|         | <b>Pharmacy &amp; Therapeutics Committee Adjourns</b><br><br><b>Break (10 mins)</b>  | All                            |
|         | <b>Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)</b>  | Kavita Chawla, Committee Chair |
|         | <b>Drug Utilization Presentation</b>   | Ryan Taketomo                  |
|         | <b>Lunch (30 mins)</b>   | All                            |
|         | Apple Health Policy:<br><b>67.70.10 Migraine Agents : Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists</b> <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul> | Luke Dearden                   |
|         | Apple Health Policy:<br><b>21.53.10 Oncology Agents : Cyclin Dependent Kinase Inhibitors</b> <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>                          | Ryan Taketomo                  |
|         | Apple Health Policy:<br><b>30.04.30 Bone Density Regulators : Calcitonins</b> <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>   | Marissa Tabile                 |
|         | <b>Musculoskeletal Therapy Agents</b> <ul style="list-style-type: none"> <li>• Fibrodysplasia Agents <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> </ul> </li> </ul>                        | Marissa Tabile                 |

*\* Stakeholders will be allowed 3 minutes for comments.*

*Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.

|  |  |  |
|--|--|--|
|  | <ul style="list-style-type: none"> <li>○ Motion</li> </ul>   |  |
|  | <b>Break (10 min)</b>  | All                                      |
|  | <b>Antihypertensives</b> <ul style="list-style-type: none"> <li>● Direct Renin Inhibitor Combinations</li> <li>● Direct Renin Inhibitors</li> <li>● Neprilysin Inhib (ARNI)-Angiotensin II Recept Antag Combinations <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>  | Nina Huynh, Prime                        |
|  | <b>Endocrine and Metabolic Agents</b> <ul style="list-style-type: none"> <li>● Insulin-Like Growth Factors</li> <li>● Natriuretic Peptides <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>  | Nina Huynh, Prime                        |
|  | <b>Analgesics</b> <ul style="list-style-type: none"> <li>● Opioid Agonists - Long Acting</li> </ul> <b>Antiemetics / Antivertigo Agents</b> <ul style="list-style-type: none"> <li>● 5-HT3 Receptor Antagonists</li> <li>● Other</li> <li>● Substance P/Neurokinin 1 (NK1) Receptor Antagonists</li> <li>● Substance P/Neurokinin 1 Receptor Antagonist Combinations</li> </ul> <b>Antivirals</b> <ul style="list-style-type: none"> <li>● Hepatitis C Agents - Direct Acting Antivirals</li> <li>● Hepatitis C Agents - Misc</li> </ul> <b>Contraceptives</b> <ul style="list-style-type: none"> <li>● Non-Hormonal - Vaginal</li> </ul> <b>Dermatologics</b> <ul style="list-style-type: none"> <li>● Gene Therapy</li> </ul> <b>Endocrine and Metabolic Agents</b> <ul style="list-style-type: none"> <li>● Adrenal Steroid Inhibitors</li> <li>● Androgens – Testosterone</li> <li>● Calcimimetic Agents – Oral</li> <li>● Cortisol Synthesis Inhibitors</li> <li>● Hereditary Tyrosinemia Type 1 (HT-1) Agents – Oral</li> <li>● Homocystinuria Agents – Oral</li> <li>● Hyperammonemia Agents – Oral</li> <li>● Mineralocorticoid Receptor Antagonists</li> <li>● Molybdenum Cofactor Deficiency (MOCD) Agents</li> <li>● Pituitary Suppressant Combinations</li> </ul> <b>Gastrointestinal Agents</b> <ul style="list-style-type: none"> <li>● Live Fecal Microbiota</li> </ul> <b>Hematological Agents</b> <ul style="list-style-type: none"> <li>● Anti-Von Willebrand Factor Agents</li> </ul> <b>Immunosuppressive Agents</b> <ul style="list-style-type: none"> <li>● Rock Inhibitors</li> </ul> <b>Migraine Agents</b> <ul style="list-style-type: none"> <li>● Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists</li> <li>● Selective Serotonin Agonists 5-HT(1)</li> </ul> <b>Ophthalmic Agents</b> <ul style="list-style-type: none"> <li>● Alpha Adrenergic Agonists</li> </ul> | Nina Huynh, Prime<br>Marissa Tabile, HCA |

*\* Stakeholders will be allowed 3 minutes for comments.*

*Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.

|           |  |                                |
|-----------|--|--------------------------------|
|           | <b>Pulmonary Hypertension Agents</b> <ul style="list-style-type: none"> <li>• Endothelin Receptor Antagonists</li> <li>• Phosphodiesterase Inhibitors (PDEI)</li> <li>• Prostacyclin Receptor Agonists</li> <li>• Prostaglandin Vasodilators</li> <li>• SGC Stimulator</li> </ul> <b>All classes in this section:</b> <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul> |                                |
| 4:40 p.m. | <b>Drug Utilization Review (DUR) Board Adjourns</b>  | Kavita Chawla, Committee Chair |

For all Apple Health (Medicaid) questions:

1. Go to [HCA Support](#).
2. Click **Public**. You will need a SecureAccess Washington (SAW) account. ([View instructions for accessing SAW.](#))
3. Once you have logged into SAW, you will see the HCA Support portal.
4. Click **Make a Request**.
5. Click the **Apple Health Pharmacy** tile. This will take you to the online form.



*\* Stakeholders will be allowed 3 minutes for comments.  
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.